Daily aggregation of the latest industry news from authoritative global and Chinese sources, with AI-generated Chinese summaries to help professionals stay ahead.
Pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter
It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.
Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification system designed to prevent underage use.
Federal programs that support brain injury research and services are in flux, with lapsed legislation and a diminished injury-tracking workforce. Still, in rural Pennsylvania, children with acquired brain injuries gathered for a summer camp that emphasized community, confidence, and fun.
Opioid settlement cash was meant to abate the addiction crisis. But a new investigation reveals millions in Louisiana was spent on law enforcement gear and police technology instead of lifesaving treatment.
A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
“We are concerned the [Lindsay] Clancy case could make psychiatrists more reluctant to treat mothers with mental illness,” write reproductive and forensic psychiatrists.
Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news
States must submit Rural Health Transformation Program progress reports to the federal government, but they aren’t required to proactively post those reports, or related information, publicly.
Despite President Donald Trump’s promises to make fertility treatment more affordable, the overall costs for one IVF cycle in the U.S. remain in the tens of thousands of dollars. So more Americans than ever are going to Europe to seek IVF treatment for a fraction of the cost.
The agreements, covering issues like drug pricing, reducing the use of synthetic food dyes, and cutting back on insurance prior authorization rules, were announced with fanfare and touted as victories. But it’s not clear whether they’ll result in lasting change.